CORRESP Filing
Silo Pharma, Inc.
Date: Nov. 24, 2025 · CIK: 0001514183 · Accession: 0001213900-25-114120
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-291129
Letter
Re: Silo Pharma, Inc.
November 24, 2025
VIA EDGAR
United States Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Attention: Tyler Howes
Form S-1 Registration Statement
File No. 333-291129
Ladies and Gentlemen:
Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Silo Pharma, Inc. (the "Company") respectfully requests that the effective date of the registration statement referred to above be accelerated so that it will become effective at 4:00 p.m., Eastern Daylight Time, on Wednesday, November 26, 2025, or as soon thereafter as possible.
Please notify Greg Carney of Sheppard, Mullin, Richter & Hampton LLP, counsel to the Company, at (213) 617-4209 as soon as possible as to the time the Registration Statement has been declared effective pursuant to this acceleration request.
SILO PHARMA, INC.
By: /s/ Eric Weisblum
Name: Eric Weisblum
Title: Chief Financial Officer
Show Raw Text
CORRESP 1 filename1.htm November 24, 2025 VIA EDGAR United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Tyler Howes Re: Silo Pharma, Inc. Form S-1 Registration Statement File No. 333-291129 Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Silo Pharma, Inc. (the "Company") respectfully requests that the effective date of the registration statement referred to above be accelerated so that it will become effective at 4:00 p.m., Eastern Daylight Time, on Wednesday, November 26, 2025, or as soon thereafter as possible. Please notify Greg Carney of Sheppard, Mullin, Richter & Hampton LLP, counsel to the Company, at (213) 617-4209 as soon as possible as to the time the Registration Statement has been declared effective pursuant to this acceleration request. SILO PHARMA, INC. By: /s/ Eric Weisblum Name: Eric Weisblum Title: Chief Financial Officer